Global Initiative for Chronic Obstructive Lung Disease. 2017. Retrieved from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd
 Dutch Apnea Society survey (Apneuvereniging) based on 75 NightBalance users for an average of 2.2 years
Page 7, most reported symptems, page 8, reported results by symptom, mean results of top 3 symptoms
 Home user trial 1 shows that 70% of chronically sleep deprived patrticipants rated their level of daytime sleepiness lower after 2 weeks than they did at baseline.
 Aug 2017 Patient Preference trial, n = 85; compared masks included Resmed Airfit F10 and F20, Respironics Amara View and F&P Simplus
 Source: April 2018 review of Apple App Store®, Google Play™ store and App Annie™
 19% of DreamMapper users used their therapy 100% of the nights over 90-days versus 12% for the Standard Care users, a 58.33% increase. In a retrospective review conducted by Philips Respironics of the EncoreAnywhere database that compared DreamMapper patients (n=85,077) to users who did not use it (n=87,602).